2025-524328-24-00CompletedPhase 1
GRT-1C102: A randomized, double-blind, placebo-controlled dose escalation study to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of GRT-001 after subcutaneous administrations to healthy subjects (MONOSqut trial).
Source: EU CTIS (euclinicaltrials.eu) · Last updated 31 Jul 2026
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- First submitted
- 23 Jan 2026
- Start date
- 6 May 2026
- Lead sponsor
- Granite Bio AG
- EU CT number
- 2025-524328-24-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 40
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Charite Research Organisation GmbH | Berlin | Germany | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.